AboutContact us
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
Nice to lay off 500 employees as it struggles to navigate the AI transition
2
From six-person startups to a $6.3 billion take-private: October's extraordinary month for Israeli tech exits
3
After years of delays, IDF prepares to deploy Elbit’s new Ro'em artillery systems
4
Israeli digital health company TailorMed acquired in $250 million deal
5
ServiceNow CEO says acquired Israeli startup Sweep helps it switch CRM customers in weeks, not years
More news

Teva

18 stories about Teva
מנכ"ל טבע החדש קור שולץ 2

New Teva CEO Kåre Schultz to Relocate to Israel

17.10.17|Golan Hazani
Mr. Schultz, who led Copenhagen-based H. Lundbeck A/S since 2015, will come to Israel and assume his new position by the end of the month
חברת ה תרופות טבע Teva

Teva’s Stock Drops After Approval of Copaxone Competitors

08.10.17|Lilach Baumer
A day after Mylan announced FDA approval for its generic versions of Copaxone, drug companies Synthon and Alvogen announce European approval for their 40 mg/ml generic versions of Teva's blockbuster drug
default image

Teva Loses Copaxone Market Exclusivity

04.10.17|Lilach Baumer
Rival Mylan received FDA approval for its generic versions of Copaxone, Teva’s flagship drug
חברת ה תרופות טבע Teva

Teva Sells Remaining Women's Health Assets

18.09.17|Lilach Baumer
After selling its Paragard business for $1.1 billion last week, Teva's remaining Women's Health business will be split between CVC Capital Partners and Foundation Consumer Healthcare in a $1.38 billion cash deal
מפעל חברת טבע הר חוצבים ירושלים

Teva Negotiating Sale of Remaining Women's Health Assets, Report Says

14.09.17|Lilach Baumer
CVC Capital Partners is nearing a $800 million deal for Teva's remaining Women's Health business, Bloomberg reported Thursday
מנכ"ל טבע החדש קור שולץ

The Ten Challenges Facing Teva's New CEO

12.09.17|Sophie Shulman
Kåre Schultz is the right man for the job, but he's facing multiple problems, from a changing market to a problematic board
default image

Teva Sells IUD Business for $1.1 Billion

12.09.17|Lilach Baumer
Going forward, the company will focus on central nervous system and respiratory treatments, shedding its Women's Health and Oncology and Pain businesses
מנכ"ל טבע החדש קור שולץ 2

New CEO to Break Teva’s Copaxone Habit

11.09.17|Sophie Shulman, Dror Reich
Troubled drugmaker says new CEO must work to quickly regain its financial credibility
קור שולץ מנכ"ל טבע החדש

Teva Appoints Lundbeck's Schultz as CEO

11.09.17|Dror Reich and Micky Grunfeld
The company’s announcement brings an end to a seven month search for a CEO to lead the troubled generic drugmaker. Updated
תרופות טבע גלולות תרופה

Bidders Line Up for Teva’s Women Health Unit, Report Says

23.08.17|Dror Reich
Church & Dwight Co. and Cooper Companies Inc. join other bidders for troubled drugmaker assets, Bloomberg reported Tuesday
Cummings Welch

U.S. Congress to Investigate Rising Multiple Sclerosis Drug Prices

21.08.17|Dror Reich
Two Congressmen are looking into the rising MS drug prices of seven pharmaceutical companies
מפעל טבע הר חוצבים ירושלים

Cerberus, Advent Eye Teva's European Assets, Report Says

15.08.17|Calcalist
The private equity firms are taking an interest in Teva's European oncology and pain treatment assets, estimated at $700 million to 1$ billion, according to a Bloomberg report
default image

Allergan Sketches Road Show to Sell Teva Stake

14.08.17|Golan Hazani
The company is in discussions with investment bankers and brokers to sell its Teva shares, said one person familiar with the matter
תרופות טבע גלולות תרופה

With Bloated Debt, Teva Looks to Sell Assets

10.08.17|Eli Shimony and Gil Kalian
The generic drugmaker said it is looking to sell Medis, an Iceland-based company it bought in 2016
מפעל חברת טבע הר חוצבים ירושלים

Teva’s Perfect Storm Sends Tel-Aviv Stock Exchange Down

06.08.17|Calcalist
Teva’s stock price dropped sharply on Thursday and Friday after the company released quarterly revenue and profits that fell short of analysts’ forecasts
מנכ"ל AstraZeneca פסקל סוריו Pascal Soriot

Soriot's Teva Appointment Unlikely, Says Activist Investor

06.08.17|Golan Hazani
Teva’s board was surprised to learn AstraZeneca's CEO Pascal Soriot will not be joining the company. Teva activist investor Benny Landa called an early report on Teva's negotiations with Mr. Soriot "devastating"
default image

Allergan Can Now Sell 9.8% Teva Stake

03.08.17|Dror Reich
Yesterday, a lock-up period on $3.2 billion worth Teva Pharmaceutical Industries’ shares owned by Allergan ended
מנכ"ל AstraZeneca פסקל סוריו Pascal Soriot

Teva in Talks to Appoint AstraZenca's Pascal Soriot as CEO

18.07.17|Golan Hazani
Mr. Soriot has met with the company’s search committee and its chairman and expressed his agreement to serve as its next CEO, people familiar with the matter said
Previous Articles